Lucinactant Discovery Laboratories

IDrugs

Volumn 5, Issue 7, 2002, Pages 696-702

  Doyle, Ian ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT EXTRACT; PHOSPHOLIPID; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; UNCLASSIFIED DRUG;

AEROSOL; ARTIFICIAL VENTILATION; CLINICAL TRIAL; DOSE CALCULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IN VIVO STUDY; LUNG ALVEOLUS SURFACE TENSION; LUNG INJURY; LUNG LAVAGE; MECONIUM ASPIRATION; NONHUMAN; OXYGEN SATURATION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 0141619370     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. 174059 Drug development pipeline: R-093777, KL4 pulmonary surfactant, RWJ-23989, Orthoclone, alniditan, prucalopride. Johnson & Johnson Company Communication 1995 March 09
2. 248081 Liquid phase synthesis of the pulmonary surfactant polypeptide KL-4. Maryanoff CA ACS 1997 213th San Francisco ORGN 281 Report of the synthesis of KL4.
3. 259708 Ansan to merge with Discovery Labs. Scrip 1997 2255 12
4. 270429 Discovery Laboratories announces completion of merger with Ansan Pharmaceuticals. Ansan Press Release 1997 November 26
5. 285780 Phase II/III clinical trial in direct ARDS with Surfaxin to be initiated by Discovery Laboratories. Discovery Laboratories Inc Press Release 1998 April 29
6. 291612 Pivotal phase II/III clinical trial enrollment begun in direct ARDS with Surfaxin by Discovery Laboratories. Discovery Laboratories Inc Press Release 1998 July 14
7. 301112 FDA awards orphan products development grant to Discovery Laboratories Inc - Agency funds clinical investigation of novel treatment for life-threatening illness of newborn infants. Discovery Laboratories Inc Press Release 1998 October 12
8. 301562 FDA designates Surfaxin Fast Track product for treatment of acute respiratory distress syndrome. Discovery Laboratories therapy demonstrates potential to address unmet medical need. Discovery Laboratories Inc Press Release 1998 October 15
9. 302120 FDA designates SURFAXIN Fast Track Product for treatment of meconium aspiration syndrome Discovery Laboratories treatment to address disease affecting 25,000 infants annually in US. Discovery Laboratories Inc Press Release 1998 October 21
10. 302176 Surfaxin. Company World Wide Web Site 1998
11. 305696 Discovery Laboratories Inc announces 1998 third quarter results. Discovery Laboratories Inc Press Release 1998 November 16
12. 313590 Discovery Laboratories Inc reports positive phase 2 Surfaxin study in MAS. Discovery Laboratories Inc Press Release 1999 February 04 Findings of a phase II comparison of Surfaxin-lavage as a treatment for MAS in newborn infants, and a report of complications associated with its use (temporary episodes of oxygen desaturation).
13. 324152 Discovery presents Surfaxin ARDS clinical data at annual meeting of the American Thoracic Society and American Lung Association. Discovery Laboratories Inc Press Release 1999 May 10
14. 324701 Discovery presents Surfaxin MAS clinical data at annual meeting of the Society for Pediatric Research. Discovery Laboratories Inc Press Release 1999 May 13
15. 333244 Discovery Laboratories Inc receives Notice of Allowance related to surfactant lavage patent application. Discovery Laboratories Inc Press Release 1999 July 20
16. 345353 Discovery Laboratories Inc completes Southern European sublicense of Surfaxin with Esteve. Discovery Laboratories Inc Press Release 1999 October 28
17. 352249 Discovery Laboratories receives broad patent covering surfactant lavage. Discovery Laboratories Inc Press Release 2000 January 12 US-06013619, published January 11, 2000, is the fifth US patent to issue in a family based on priority documents dating back to January 1988 filed by the Scripps Institute. The four earlier patents are US-05164369, US-05260273, US-05407914 and US-05789381. This latest US patent claims a method of pulmonary lavage, whereas the earlier cases claimed agents used in such methods. The equivalent PCT application, filed in January 1989 designating Europe, Japan, Scandinavian and Australia is WO-08906657. EP-00350506 is the corresponding European application.
18. 353636 Discovery Laboratories Inc to begin pivotal phase III study of Surfaxin in meconium aspiration syndrome. Discovery Laboratories Inc Press Release 2000 January 27
19. 357077 Discovery to begin exploration of Surfaxin platform for aerosolized formulations for asthma and other respiratory diseases. Discovery Laboratories Inc Press Release 2000 February 24
20. 361765 Discovery Laboratories Inc announces the appointment of Dr Timothy J Gregory. Discovery Laboratories Inc Press Release 2000 April 05
21. 390192 Discovery Laboratories, Inc. receives FDA clearance to begin Surfaxin clinical trial - Phase II trial to begin in acute respiratory distress syndrome. Discovery Laboratories Inc Press Release 2000 November 16
22. 399990 Discovery Laboratories Inc addresses plans to conduct a Surfaxin trial in Latin America. Discovery Laboratories Inc Press Release 2001 February 23
23. 400846 Discovery Labs proposes non-placebo arm for Surfaxin Latin American trial. FDC Reports Pink Sheet 2001 63 9 20
24. 404160 Discovery Laboratories receives FDA agreement on pivotal phase III IRDS trial design. Discovery Laboratories Inc Press Release 2001 April 04
25. 414876 Discovery Laboratories launches pivotal phase III IRDS trial. Discovery Laboratories Inc Press Release 2001 July 09
26. 419114 Discovery Laboratories announces second quarter 2001 results. Discovery Laboratories Inc Press Release 2001 August 14
27. 422819 Discovery Laboratories launches phase III IRDS clinical trial in Europe and United States. Discovery Laboratories Inc Press Release 2001 September 21
28. 440083 European Orphan product designation awarded to Discovery's Surfaxin for acute lung injury. Discovery Laboratories Inc Press Release 2002 February 15
29. 442738 Discovery Laboratories & Esteve expand relationship to develop and commercialize Surfaxin in Europe. Discovery Laboratories Inc Press Release 2002 March 07
30. 445166 Discovery Laboratories reports fourth quarter and 2001 year end financial results. Discovery Laboratories Inc Press Release 2002 March 28
31. 445270 Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG Am J Respir Crit Care Med 1999 160 4 1188-1195
32. 445282 Oxidative inactivation of surfactants. Andersson S, Kheiter A, Merritt TA Lung 1999 177 3 179-189 Study reporting the effect of cycling and ROS on KL4-surfactant surface activity.
33. 445285 Surfactant lavage treatment in a model of respiratory distress syndrome. Cochrane CG, Revak SD Chest 1999 116 1 Suppl 85S-86S Comparative study of the in vivo efficacy of lung wash versus bolus administration of KL4-surfactant in a LPS-induced model of lung injury.
34. 445306 Effects of a cationic and hydrophobic peptide, KL4, on model lung surfactant lipid monolayers. Ma J, Koppenol S, Yu H, Zografi G Biophys J 1998 74 4 1899-1907
35. 445307 Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Cochrane CG, Revak SD, Merritt TA, Schraufstaetter IU, Hoch RC, Henderson C, Andersson S, Takamori H, Oades ZG Pediatr Res 1998 44 5 705-715
36. 445310 Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats. Walther FJ, Hernandez-Juviel J, Bruni R, Waring AJ Pediatr Res 1998 43 5 666-673
37. 445314 Inhibitory effects of oxyradicals on surfactant function: Utilizing in vitro Fenton reaction. Amirkhanian JD, Merritt TA Lung 1998 176 1 63-72
38. 445377 Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Walther FJ, Hernandez-Juviel J, Bruni R, Waring AJ Am J Respir Crit Care Med 1997 156 3 Part 1 855-861
39. 445386 Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL-4 following surface area cycling and addition of fibrinogen. Manalo E, Merritt TA, Amirkhanian JD, Kheiter A Lung 1997 175 4 225-233 Study reporting the effect of cycling and serum proteins on KL4-surfactant surface activity.
40. 445390 Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL-4. Manalo E, Mernitt TA, Kheiter A, Amirkhanian J, Cochrane C Pediatr Res 1996 39b 947-952
41. 445394 Exogenous surfactants in a piglet model of acute respiratory distress syndrome. Sood SL, Balaraman V, Finn KC, Britton B, Uyehara CF, Easa D Am J Respir Crit Care Med 1996 153 2 820-828
42. 445397 Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW, Kheiter A Pediatr Res 1996 39 4 Part 1 715-724
43. 445403 The efficacy and safety of KL-4-surfactant in preterm infants with respiratory distress syndrome. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS Am J Respir Crit Care Med 1996 153 1 404-410
44. 445405 The 21-residue surfactant peptide (LysLeu-4)-4Lys(KL-4) is a transmembrane α-helix with a mixed nonpolar/polar surface. Gustafsson M, Vandenbussche G, Curstedt T, Johansson J, Ruysschaert JM Febs Lett 1996 384 2 185-188
45. 445407 The influence of pH on surface properties of lung surfactants. Amirkhanian JD, Merritt TA Lung 1995 173 4 243-254
46. 445431 Comparative evaluation of reduction in surface-tension lowering ability of Survanta and KL-4 surfactant by some serum components. Amirkhanian JD, Kheiter A, Merritt TA Pediatr Res 1994 35 4 Part 2 324A
47. 457519 Pulmonary surfactant protein B (SP-B): Structure-function relationships. Cochrane CG, Revak SD Science 1991 254 5031 566-568
48. 457523 The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants. Revak SD, Merritt TA, Hallman M, Heldt G, La Polla RJ, Hoey K, Hougten RA, Cochrane CG Pediatr Res 1991 29 5 460-465 Description of the composition of KL4-surfactant.
49. 457530 Protein-phospholipid interactions in pulmonary surfactant. The Parker B Francis Lectureship. Cochrane CG, Revak SD Chest 1994 105 3 54S-62S
50. 457534 Biophysical and biological activity of a synthetic 8.7-kDa hydrophobic pulmonary surfactant protein SP-B. Sarin VK, Gupta S, Leung TK, Taylor VE, Ohning BL, Whitsett JA, Fox JL Proc Natl Acad Sci USA 1990 87 7 2633-2637 Description of the biophysical properties of SP-B.
51. 457538 Surfactant inhibition by plasma proteins: Differential sensitivity of various surfactant preparations. Seeger W, Grube C, Gunther A, Schmidt R Eur Respir J 1993 6 7 971-977
52. 457540 The fate of exogenous surfactant in neonates with respiratory distress syndrome. Hallman M, Merritt TA, Bry K Clin Pharm 1994 26 3 215-232 Valuable overview of surfactant kinetics.
53. 457549 Alveolar and tissue surfactant pool sizes in humans. Rebello CM, Jobe AH, Eisele JW, Ikegami M Am J Respir Crit Care Med 1996 154 3 Pt 1 625-628 Surfactant phospholipid content in humans.
54. 457553 Surfactant metabolism. Jobe AH, Ikegami M Clin Perinatol 1993 20 4 683-696
55. 457555 Lavage administration of dilute surfactants after acute lung injury in neonatal piglets. Balaraman V, Meister J, Ku TL, Sood SL, Tam E, Kileen J, Uyehara CF, Egan E, Easa D Am J Respir Crit Care Med 1998 158 1 12-17 Study reporting the efficacy of lavaging with dilute and concentrated surfactants in a lavage-depleted in vivo model.